Phaseline

Targets › GREM1

GREM1 (Gremlin-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Cytokine that may play an important role during carcinogenesis and metanephric kidney organogenesis, as a BMP antagonist required for early limb outgrowth and patterning in maintaining the FGF4-SHH feedback loop. Down-regulates the BMP4 signaling in a dose-dependent manner (By similarity). (UniProt, O60565)

Open in Phaseline: the race on GREM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Transcenta Therapeutics (Hangzhou)TST003
humanized anti-GREM1 monoclonal antibody
GREM1Phase 1Locally Advanced Solid TumorJun 2027

Conditions

Locally Advanced Solid Tumor (1)

Modalities

small molecule (1)

Companies

Transcenta Therapeutics (Hangzhou) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.